Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc

Bullboard Posts

Comment by bilosellhion Oct 30, 2003 6:13pm

380 Views

Post# 6583845

RE: Price

There are many positives about the NCI partnership, as others have pointed out, but I do wonder if it will slow use (sic) down. huh? what are the chances that nci will be any slower than the current ph II prostate & glio trials? that is the primary reason i am pleased with this development - that a credible US based entity will take the lead on conducting the trials, which will add credibility and objectivity to the results, and if the results are as good as hoped for, they will make the path to approval much easier. this is the next best possible happening other than a partnership with a big pharma. onc & BT should just give these guys a single reactor run of reolysin and get the H*LL out of the way.